Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a ...

Curium’s Investigational New Drug (IND) application for 177Lu-PSMA-I&T, a therapeutic agent for patients with metastatic ...

PSMAddition is an international, open-label, prospective, phase 3 randomized controlled trial of 177Lu-PSMA-617 plus ADT and ARPI in PSMA-positive mHSPC.

Join Tom and Mike as they share an important update on Tom's prostate cancer journey. In this video, they discuss Tom's ...

The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...

The results to be presented by Prof Emmett at the EAU Congress 2026 will expand on the earlier findings that the trial met its primary endpoint, demonstrating that 64 Cu-SAR-bisPSMA positron emission ...

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...

Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a ...